Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Treasury Shares (2016 - 2025)

Viking Therapeutics' Treasury Shares history spans 10 years, with the latest figure at $2.9 million for Q4 2023.

  • For Q4 2023, Treasury Shares rose 1459.66% year-over-year to $2.9 million; the TTM value through Dec 2023 reached $2.9 million, up 1459.66%, while the annual FY2023 figure was $2.9 million, 30.2% up from the prior year.
  • Treasury Shares for Q4 2023 was $6.8 million at Viking Therapeutics, roughly flat from $6.8 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $2.9 million in Q4 2023 and bottomed at $183095.0 in Q2 2019.
  • The 5-year median for Treasury Shares is $995299.0 (2021), against an average of $1.1 million.
  • The largest YoY upside for Treasury Shares was 32.69% in 2023 against a maximum downside of 0.0% in 2023.
  • A 2-year view of Treasury Shares shows it stood at $6.8 million in 2022, then changed by 0.0% to $6.8 million in 2023.
  • Per Business Quant, the three most recent readings for VKTX's Treasury Shares are $2.9 million (Q4 2023), $2.2 million (Q3 2023), and $2.2 million (Q2 2023).